Journal ArticleDOI
Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency
Giuseppe Maschio,Daniele Alberti,Gérard Janin,Francesco Locatelli,Johannes F.E. Mann,Mario Motolese,Claudio Ponticelli,Eberhard Ritz,Pietro Zucchelli +8 more
Reads0
Chats0
TLDR
A study to determine the effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases.Abstract:
Background Drugs that inhibit angiotensin-converting enzyme slow the progression of renal insufficiency in patients with diabetic nephropathy. Whether these drugs have a similar action in patients with other renal diseases is not known. We conducted a study to determine the effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases. Methods In a three-year trial involving 583 patients with renal insufficiency caused by various disorders, 300 patients received benazepril and 283 received placebo. The underlying diseases included glomerulopathies (in 192 patients), interstitial nephritis (in 105), nephrosclerosis (in 97), polycystic kidney disease (in 64), diabetic nephropathy (in 21), and miscellaneous or unknown disorders (in 104). The severity of renal insufficiency was classified according to the base-line creatinine clearance: 227 patients had mild insufficiency (creatinine clearance, 46 to 60 ml per minu...read more
Citations
More filters
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (NIH Publication No. 98-4080)
Black Hr,Cohen Jd,Kaplan Nm,Ferdinand Kc,Chobanian Av,Dustan Hp,Gifford Rw,M. Moser,Sheps Sg,L. Agodoa,August Pa,Bakris Gl,V. Burt,W. Busse,Carter Bl,Chesley Fd,J. Cleeman,Cohn Jn,Cregler Ll,C. Crespo,Cushman Wc,J. Cutler,Darrow Md,DeQuattro Vl,Devereux Rb,Dworkin Ld,Elliott Wj,M. Epstein,B. Falkner,Ferrario Cm,Flack Jm,W. Frishman,Frohlich Ed,Green La,Grimm Rh,Hagberg Jm,Hall Wd,J. Handler,S. Havas,Hill Mn,Horan Mj,Hsueh Wa,Hyman Bn,Izzo Jl,K. Jamerson,Kiley Jp,Kochar Ms,Kolasa Km,Krakoff Lr,D. Levy,Lindheimer Md,Luepker Rv,Malone Mel,B. Massie,Materson Bj,J. Merchant,Messerli Fh,Miller Nh,Moore Ma,L. MustoneAlexander,S. Oparil,Perry Hm,Pickering Tg,Pratt Jh,Ram Cvs,Randall Os,Reed Jw,Roberts Rw,Roccella Ej,Rogus Sd,E. Saunders,E. Schron,G. Schwartz,Sibai Bm,D. Snyder,Sowers Jr,J. Stamler,R. Temple,S. Textor,T. Thom,Vidt Dg,M. Weber,Weinberger Mh,R. Weinshilboum,Whelton Pk,Whisnant Jp,Wiebers Do,Winston Mc,Wright Jt,C. Lenfant,L. Casser,Colman Pj,T. Edwards,Feeley Dm,J. Gajewski,D. Levine,W. Manger,Marshall Ec,Nickey Wa,Robert Rw,Secrest Bg,Singer Eh,Wilson Gj,Young Jm,Bachman Jw,Campese Vm,Carr Aa,M. Hand,Holden Dc,Jamieson Mj,S. Julius,Mensah Ga,M. Prisant,Sullivan Jm,Wilson Dj,G. Morosco,Anderson De,D. Waugh +117 more
TL;DR: In older persons, diuretics are preferred and long-acting dihydropyridine calcium antagonists may be considered and specific therapy for patients with LVH, coronary artery disease, and heart failure are outlined.
Journal ArticleDOI
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial
Jackson T. Wright,George L. Bakris,Tom Greene,L. Y. Agodoa,Lawrence J. Appel,Jeanne Charleston,De Anna Cheek,Janice G. Douglas-Baltimore,J. Gassman,Richard J. Glassock,Lee Hebert,Kenneth Jamerson,Julia B. Lewis,Robert A. Phillips,Robert D. Toto,John P. Middleton,Stephen G. Rostand +16 more
TL;DR: Angiotensin-converting enzyme inhibitors appear to be more effective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline in hypertension.
Journal ArticleDOI
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
Journal ArticleDOI
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
TL;DR: The Task Force has summarized the most important clinical issues on coronary heart disease prevention on which there is good agreement in order to give cardiologists and physicians, and other health care professionals, the best possible advice to facilitate their work on coronaryHeart disease prevention.
References
More filters
Journal ArticleDOI
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft,M H Gault +1 more
TL;DR: A formula has been developed to predict Creatinine clearance from serum creatinine (Scr) in adult males: Ccr = (140 – age) (wt kg)/72 × Scr (mg/100ml) (15% less i).
Journal ArticleDOI
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group
TL;DR: Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
Journal ArticleDOI
The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease
Saulo Klahr,Andrew S. Levey,Gerald J. Beck,Arlene W. Caggiula,Lawrence G. Hunsicker,John W. Kusek,Gary E. Striker +6 more
TL;DR: Restricting protein intake and controlling hypertension delay the progression of renal disease in animals and in patients with various chronic renal diseases.
Journal ArticleDOI
The number needed to treat: a clinically useful measure of treatment effect.
Richard J. Cook,David L. Sackett +1 more
TL;DR: The relative benefit of an active treatment over a control is usually expressed as the relative risk, the Relative risk reduction, or the odds ratio, but for clinical decision making, it is more meaningful to use the measure "number needed to treat."
Journal ArticleDOI
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
TL;DR: Control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass, and failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomersular lesions comparable to those seen in untreated group 4 rats.